Medical oncologists discuss the role for comprehensive next-generation sequencing (NGS) in upper GI cancers and the potential role for zolbetuximab.
An Embarrassment of Riches Treatment Sequencing in Gastrointestinal Cancers
Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Antitumor Activity Seen With Olverembatinib in GIST Subtype
Olverembatinib has shown promising clinical efficacy in SDH-deficient gastrointestinal stromal tumors, says Haibo Qiu, MD.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
Camrelizumab Combo Improves PFS/OS Vs Sorafenib in Advanced HCC
The median progression-free survival and overall survival was extended with rivoceranib among those with unresectable HCC in the CARES-310 trial.
Sustained Responses Achieved With Zanidatamab in HER2+ Biliary Tract Cancer
The safety profile of zanidatamab in the HERIZON-BTC-01 trial appears to remain consistent after longer follow-up.